Document text
Principal Investigator: Kartik Chandran
Organization: ALBERT EINSTEIN COLLEGE OF MEDICINE
Fiscal Year: 2024
Award: $13,946,446
Funding agency: National Institute of Allergy and Infectious Diseases
The overarching goal of PROVIDENT (Prepositioning Optimized Strategies for Vaccines and Immunotherapeu-
tics against Diverse Emerging Infectious Threats) is to deliver “plug-and-play” vaccine and therapeutic an-
tibody blueprints for emerging enveloped RNA viruses belonging to three families—Nairoviridae, Han-
taviridae, and Paramyxoviridae. PROVIDENT is a highly interwoven partnership among 13 institutional
teams from academia, government, and industry. Central to PROVIDENT is its focus on platform strategies
that can rapidly advance manufacturable products with pathways to regulatory approval and plans for their
commercialization through industry partners who are integral to our consortium. PROVIDENT will accomplish
its goals by synthesizing the activities of four Research Projects, supported by three Research Cores and a
Data Management Core, and overseen by the Administrative Core. Using a prototype virus strategy in Phase I,
we will: (i) discover and dissect host factors and pathways critical for viral infection and pathogenesis and de-
liver tools to other PROVIDENT components to facilitate vaccine and immunotherapeutic development; (ii) use
advanced antigen engineering to refine vaccine design strategies through iterative assessments of immuno-
genicity and protective efficacy to generate optimized vaccine immunogens; (iii) develop RNA vaccines and
evaluate two platforms to optimize immunogenicity, protective efficacy, and safety and (iv) generate an adap-
tive antibody development pipeline that will complement and inform vaccine design strategies. In Phase II, we
will evaluate our prototype-optimized vaccine platforms against our divergent outgroup viruses in a series of
timed exercises we term “sprints,” which seek to generate a vaccine product ready to immunize animals in 10
days. In doing so, we will perform cross-family validations of our vaccine platforms for nairoviruses, han-
taviruses, and paramyxoviruses as a rigorous challenge to the generalizability of the Phase I blueprint deliver-
able, and either validate the blueprint or identify weaknesses for further refinement.
Terms: <Ab-mediated immunity><Ab-mediated protection><Academia><Achievement><Achievement Attainment><Advanced Development><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody Repertoire><Antibody Response><Antibody immunity><Antibody protection><Antibody-mediated protection><Antigens><Assay><Bioassay><Biological><Biological Assay><Bispecific Monoclonal Antibodies><Blood Vessels><Bunyavirus><Cell Body><Cell Surface Antigens><Cells><Cellular Immunology><Collaborations><Complement><Complement Proteins><Critical Paths><Critical Pathways><Development><Disease><Disease Outbreaks><Disorder><Dissection><Dose><Engineering><Evaluation><Event><Exercise><Family><Future><Genetic><Genotype><Glycoproteins><Goals><Government><Hantavirus><Host Factor><Host Factor Protein><Human><Immune response><Immunize><Immunochemical Immunologic><Immunologic><Immunologic Surface Markers><Immunological><Immunological Surface Markers><Immunological response><Immunologically><Immunologics><Immunotherapeutic agent><Industry><Infection><Institution><Integration Host Factors><Knowledge><Lead><Maps><Mining><Modern Man><Molecular><Nairovirus><Non-Polyadenylated RNA><Orthobunyavirus><Outbreaks><Paramyxoviridae><Paramyxovirus><Pathogenesis><Pathogenicity><Pathway interactions><Pb element><Phase><Play><Position><Positioning Attribute><Proteins><Proteomics><R-Series Research Projects><R01 Mechanism><R01 Program><RNA><RNA Gene Products><RNA Viruses><RNA vaccine><RNA-based vaccine><Receptor Protein><Recombinants><Research><Research Grants><Research Project Grants><Research Projects><Ribonucleic Acid><Risk Assessment><Safety><Series><Serotyping><Structure><Surface Antigens><T cell response><Testing><Therapeutic><Therapeutic Uses><Therapeutic antibodies><Toxin><Transgenic Animals><Vaccination><Vaccine Design><Vaccines><Validation><Viral><Viral Diseases><Viral Pathogenesis><Virus><Virus Diseases><antibody-mediated immunity><bi-specific monoclonal antibodies><biologic><clinical translation><clinically translatable><commercialization><complementation><data management><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><endothelial dysfunction><epidemic concern><epidemic potential><epidemic risk><epidemic threat><experiment><experimental research><experimental study><experiments><heavy metal Pb><heavy metal lead><host response><immune drugs><immune system response><immune-based therapeutics><immunogen><immunogenicity><immunologic therapeutics><immunoresponse><immunotherapeutics><immunotherapy agent><in vivo><industrial partnership><industry partner><industry partnership><mRNA vaccine><mRNA-based vaccine><member><model of animal><non-human primate><nonhuman primate><pandemic concern><pandemic potential><pandemic risk><pandemic threat><pathway><prophylactic><protective efficacy><prototype><receptor><response><risk mitigation><safety assessment><structural biology><tool><vaccine antibodies><vaccine development><vaccine induced antibodies><vaccine platform><vaccine strategy><vaccine-induced antibodies><validations><vascular><viral infection><viral infection mechanism><virology><virus host interaction><virus infection><virus infection mechanism><virus pathogenesis><virus-induced disease>